休闲体力活动与非转移性前列腺癌患者前列腺癌特异性死亡的关系
美国前瞻性队列研究纳入非转移性前列腺癌患者,诊断前分析7328例、诊断后分析5319例。诊断前每周≥17.5 MET-h休闲体力活动仅与较低危肿瘤(Gleason 2-7且T1-T2)患者前列腺癌特异性死亡风险降低37%相关;诊断后同等活动量与总体前列腺癌特异性死亡风险降低31%相关,且不因肿瘤风险类别而异。
要点
- 诊断前每周≥17.5 MET-h体力活动与较低危肿瘤患者前列腺癌特异性死亡风险降低37%相关。
- 诊断后每周≥17.5 MET-h体力活动与总体前列腺癌特异性死亡风险降低31%相关,不因肿瘤风险类别而异。
- 诊断后步行与前列腺癌特异性死亡呈提示性负相关(p趋势=0.07)。
核心结论
- 研究结果为前列腺癌幸存者坚持体力活动推荐提供了额外证据,并支持在前列腺癌幸存者中开展以进展或死亡为结局的运动临床试验。
研究设计与样本
- 美国前瞻性队列研究,纳入1992/1993年至2011年6月诊断的非转移性前列腺癌男性,随访死亡至2012年。
- 诊断前分析纳入7328例,诊断后分析纳入5319例。
主要发现
- 诊断前随访期间发生454例前列腺癌死亡,诊断后随访期间发生261例前列腺癌死亡。
- 诊断前每周≥17.5 MET-h休闲体力活动相比3.5-<8.75 MET-h/wk,仅在较低危肿瘤(Gleason评分2-7且T1-T2)男性中与前列腺癌特异性死亡风险显著降低37%相关(HR 0.63,95%CI 0.43-0.91,p趋势=0.03;交互作用p=0.02)。
- 诊断前步行可见类似结果,其他休闲体力活动未见类似结果。
- 诊断后同等比较(≥17.5 vs 3.5-<8.75 MET-h/wk)与总体前列腺癌特异性死亡风险显著降低31%相关(HR 0.69,95%CI 0.49-0.95,p趋势=0.006),且不因肿瘤风险类别而异。
- 诊断后步行与前列腺癌特异性死亡呈提示性负相关(p趋势=0.07)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结果为观察性,可能不适用于转移性前列腺癌患者。
- 不能排除较低危肿瘤男性筛查率较高所致的残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Large prospective cohort studies need to confirm the associations between recreational physical activity (PA), including the most common type-walking, and prostate cancer-specific mortality (PCSM) among prostate cancer patients. OBJECTIVE: To investigate the associations of recreational PA, reported before and after diagnosis, with PCSM, overall and by tumor risk category. DESIGN, SETTING, AND PARTICIPANTS: In a prospective cohort study conducted in the USA, men diagnosed with nonmetastatic prostate cancer between 1992/1993 and June 2011 were followed for mortality until 2012. Patients were included in pre- (n=7328) and/or postdiagnosis (n=5319) analyses. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazards models were used to assess PCSM with recreational PA. RESULTS AND LIMITATIONS: A total of 454 and 261 prostate cancer deaths occurred during pre- and postdiagnosis follow-up, respectively. Prior to diagnosis, engaging in ≥17.5 metabolic equivalent hours per week (MET-h/wk) of recreational PA, compared with 3.5-<8.75 MET-h/wk, was associated with a significant 37% lower risk of PCSM (hazard ratio: 0.63, 95% confidence interval: 0.43-0.91, p trend=0.03) only among men with lower-risk tumors (Gleason score 2-7 and T1-T2; p interaction=0.02). A similar result was seen for walking but not for other recreational PA. After diagnosis, the same comparison (≥17.5 vs 3.5-<8.75 MET-h/wk) was associated with a significant 31% lower risk of overall PCSM (hazard ratio: 0.69, 95% confidence interval: 0.49-0.95, p trend=0.006), which did not differ by tumor risk category. Postdiagnosis walking had a suggestive inverse association with PCSM (p trend=0.07). These results were observational and may not be generalized to patients with metastatic prostate cancer. Residual confounding due to a higher screening rate among men with lower-risk tumors cannot be ruled out. CONCLUSIONS: The findings provide additional evidence for prostate cancer survivors to adhere to PA recommendations, and support clinical trials of exercise among prostate cancer survivors with progression or mortality as outcomes. PATIENT SUMMARY: In a large follow-up study of men diagnosed with nonmetastatic prostate cancer, those who exercise more after diagnosis had a lower risk of dying from prostate cancer.
引用
- Wang Y, Jacobs EJ, Gapstur SM, et al. Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer. Eur Urol. 2017. PMID: 28711382. doi:10.1016/j.eururo.2017.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。